New hope for advanced cancer: Immune-Boosting drug combo tested in japan
NCT ID NCT03233139
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tests the safety of cemiplimab, a drug that helps the immune system fight cancer, alone or with other drugs in Japanese patients with advanced malignancies, especially lung cancer. About 146 participants will receive different combinations to see if tumors shrink and how the body handles the drugs. The goal is to find safe and effective doses for future larger studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cemiplimab (also known as Libtayo), fianlimab, and various chemotherapy drugs
What this could lead to
If successful, this could show that cemiplimab and similar drugs are safe and effective for Japanese patients with advanced lung cancer, potentially expanding treatment options.
What could go wrong
This is an early-phase trial with a small number of participants, so results may not apply to all patients. Side effects from immune-boosting drugs can be serious, and the combination treatments may not work better than existing options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Gunma Prefectural Cancer Center
Ōta, Gunma, 373-8550, Japan
-
Hiroshima City Hiroshima Citiz
Hiroshima, 730-8518, Japan
-
Kanagawa Cancer Center - Thora
Yokohama, Kanagawa, 241-8515, Japan
-
Kanagawa Cardiovascular and Respiratory Center
Yokohama, Kanagawa, 236-0051, Japan
-
Kanazawa University Hospital
Kanazawa, Ishikawa-ken, 920-8641, Japan
-
Kansai Medical University Hirakata Hospital
Hirakata, Osaka, 573-1191, Japan
-
Kitasato University Hospital
Sagamihara, Kanagawa, 252-0375, Japan
-
Kobe City Medical Center General Hospital
Kobe, Hyōgo, 650-0047, Japan
-
Kurashiki Central Hospital
Kurashiki, Okayama-ken, 710-8602, Japan
-
Kurume University Hospital
Kurume, Fukuoka, 830-0011, Japan
-
Nagasaki University Hospital
Nagasaki, 852-8501, Japan
-
National Cancer Center Hospital - Tsukiji Campus
Chuo Ku, Tokyo, 104-0045, Japan
-
National Hospital Organization Kinki-chuo Chest Medical Center
Sakai-shi, Osaka, 591-8555, Japan
-
National Hospital Organization Nagoya Medical Center
Nagoya, Aichi-ken, 460-0001, Japan
-
Osaka International Cancer Institute
Osaka, 541-8567, Japan
-
Osaka Medical and Pharmaceutical University Hospital
Takatsuki, Osaka, 569-8686, Japan
-
Osaka Metropolitan University Hospital
Osaka, Osaka, 545-8586, Japan
-
Saitama Cancer Center
Shinden, Saitama, 362-0806, Japan
-
Sasebo City General Hospital
Sasebo, Nagasaki, 857-8511, Japan
-
Tokushima University Hospital
Tokushima, 770-8503, Japan